Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma

NCT00440388 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.

NCT NCT00440388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00440388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma
Lead sponsor
Ascenta Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
November 30, 2008
Enrollment
23 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma